Administration of finerenone in chronic kidney disease
Spironolactone is a first-generation and non-selective mineralocorticoid receptor antagonist (MRA). It is extensively well-studied and recommended due to increased accessibility for patients. Unfortunately, it is often discontinued in several cases due to its association with hyperkalemia. The appar...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Book |
| Published: |
Society of Diabetic Nephropathy Prevention,
2023-01-01T00:00:00Z.
|
| Subjects: | |
| Online Access: | Connect to this object online. |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|